CN109793811B - Ganoderma preparation with effects of inhibiting prostatic hyperplasia, protecting liver and enhancing immunity - Google Patents
Ganoderma preparation with effects of inhibiting prostatic hyperplasia, protecting liver and enhancing immunity Download PDFInfo
- Publication number
- CN109793811B CN109793811B CN201910234660.9A CN201910234660A CN109793811B CN 109793811 B CN109793811 B CN 109793811B CN 201910234660 A CN201910234660 A CN 201910234660A CN 109793811 B CN109793811 B CN 109793811B
- Authority
- CN
- China
- Prior art keywords
- ganoderma
- content
- ganoderic acid
- ganoderic
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity, which comprises, by mass, 2.5-3.5% of ganoderma lucidum polysaccharide, 1.8-2.4% of astragalus polysaccharide, 0.0008-0.0012% of ganoderic acid A, 0.0004-0.0006% of ganoderic acid G, 0.0004-0.0006% of ganoderic acid D, 0.0007-0.0009% of ganoderic ketone triol and 0.0004-0.0006% of ganoderic acid DM. On the basis of inhibiting prostatic hyperplasia and protecting liver, the ganoderma lucidum preparation is compatible with astragalus root, the effects of inhibiting prostatic hyperplasia, protecting and nourishing liver and improving immunity of various medicinal materials are synergistically exerted, and the obtained ganoderma lucidum tablets can inhibit prostatic hyperplasia, improve chronic hepatitis and effectively prevent relapse and deterioration of diseases.
Description
Technical Field
The invention belongs to the technical field of medical health products, and particularly relates to a ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity.
Background
Benign Prostatic Hyperplasia (BPH) is the hyperproliferation of prostate epithelial and stromal cells, resulting in an increase in prostate volume and thus clinical symptoms such as frequency and urgency of urination. Benign prostatic hyperplasia, which is commonly found after the age of 40 years, occurs more than 50% by the age of 60 years, and is up to 83% by the age of 80 years, and prostate disease has become the most prevalent disease in the elderly male population. With the development of the aging process in China, the disease incidence rate and the number of people will also rise. The effect of endocrine drug therapy and therapy by surgery, radiotherapy and chemotherapy is not very ideal, and the therapy also brings certain side effects. In recent years, on the basis that ganoderma has biological activities of improving immunity, resisting cancer, reducing blood sugar, resisting fatigue and the like, the inventor finds that the ethanol extract and the triterpene component of ganoderma have the effects of remarkably inhibiting prostate cell proliferation and inhibiting the receptor expression of male hormone on prostate, and ganoderma and Chinese herbal medicines have better synergistic advantages in the aspect of preventing and treating BPH, so that the toxic and side effects are small, the pain of patients can be effectively relieved, and the life quality is improved.
The liver is the main organ for detoxifying the body and regulating the balance of sugar and lipid metabolism. With the improvement of living standard and the change of living environment (water, air, food, etc.), the incidence of liver diseases is on the rising trend year by year. Such as viral hepatitis, heterogenous liver injury (caused by alcohol or drugs, pesticides, carcinogens and the like), hepatic fibrosis, autoimmune hepatitis and the like seriously threaten human health in the global range. Clinically, various drugs can also cause liver injury, such as antibacterial drugs, non-steroidal anti-inflammatory drugs, central depressant drugs, antitumor drugs, antithyroid drugs, immunosuppressants, hypoglycemic drugs, lipid-lowering drugs and the like. In addition, liver-protecting drugs themselves have potential liver damage problems. The currently developed liver-protecting medicines mainly comprise synthetic medicines, and the medicines have large toxic and side effects, so that the search for natural medicines without toxic and side effects for preventing and treating liver diseases is urgent.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
The present invention has been made in view of the above-mentioned technical drawbacks.
Therefore, as one aspect of the invention, the invention overcomes the defects in the prior art and provides the ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity.
In order to solve the technical problems, the invention provides the following technical scheme: a Ganoderma preparation with effects of inhibiting prostatic hyperplasia, protecting liver, and enhancing immunity comprises ganoderan, Astragalus polysaccharides, ganoderic acid A, ganoderic acid G, ganoderic acid D, ganoderic ketotriol and ganoderic acid DM;
wherein, the content of ganoderan is 2.5-3.5%, the content of astragalus polysaccharide is 1.8-2.4%, the content of ganoderic acid A is 0.0008-0.0012%, the content of ganoderic acid G is 0.0004-0.0006%, the content of ganoderic acid D is 0.0004-0.0006%, the content of ganoderic ketone triol is 0.0007-0.0009%, and the content of ganoderic acid DM is 0.0004-0.0006%.
As a preferred scheme of the ganoderma preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity, the ganoderma preparation comprises the following components in percentage by weight: by mass percentage, the content of ganoderan is 3.0%, the content of astragalus polysaccharide is 2.1%, the content of ganoderic acid A is 0.001%, the content of ganoderic acid G is 0.0005%, the content of ganoderic acid D is 0.0005%, the content of ganoderic ketone triol is 0.0008%, and the content of ganoderic acid DM is 0.0005%.
As a preferred scheme of the ganoderma preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity, the ganoderma preparation comprises the following components in percentage by weight: the Ganoderma preparation comprises Ganoderma alcohol extract, Ganoderma water extract, and radix astragali water extract.
As a preferred scheme of the ganoderma preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity, the ganoderma preparation comprises the following components in percentage by weight: the preparation method of the ganoderma lucidum preparation comprises the following steps,
preparing the ganoderma lucidum alcohol extract: drying and pulverizing Ganoderma fruiting body, adding ethanol, extracting under reflux, filtering, collecting residue and filtrate, concentrating the filtrate to obtain concentrated solution, spray drying, and pulverizing to obtain Ganoderma alcoholic extract;
preparing a ganoderma aqueous extract: heating and extracting the filter residue, and concentrating to obtain a ganoderma aqueous extract;
preparing an astragalus aqueous extract: heating and extracting radix astragali, and concentrating to obtain radix astragali water extract; mixing the Ganoderma alcohol extract, Ganoderma water extract, and radix astragali water extract.
As a preferred scheme of the ganoderma preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity, the ganoderma preparation comprises the following components in percentage by weight: the preparation method of the ganoderma alcohol extract comprises the steps of drying and crushing 1 part by weight of ganoderma sporocarp to 20-40 meshes, adding 80-95% ethanol, soaking for 2 hours, carrying out hot reflux extraction for 2 times, filtering and collecting filter residues, and carrying out vacuum filtration on the filtrate at 60-75 ℃ according to the weight ratio of 1: concentrating for 1 volume to obtain concentrated solution, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, and spray drying and pulverizing to obtain the final product.
As a preferred scheme of the ganoderma preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity, the ganoderma preparation comprises the following components in percentage by weight: and carrying out hot reflux extraction at the temperature of 70-80 ℃.
As a preferred scheme of the ganoderma preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity, the ganoderma preparation comprises the following components in percentage by weight: the preparation of the ganoderma aqueous extract comprises the steps of air-drying the filter residue, extracting for 2 times by using 10 times of drinking water by volume at 100 ℃ for 1 hour each time, adding a small amount of water for washing, filtering, combining the aqueous extracts, and vacuumizing for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, spray drying, and pulverizing to obtain Ganoderma aqueous extract.
As a preferred scheme of the ganoderma preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity, the ganoderma preparation comprises the following components in percentage by weight: the preparation of the astragalus aqueous extract comprises the steps of crushing 4 parts of dried astragalus to 2-10 meshes, adding 20 times of drinking water by volume, extracting for 2 times at 100 ℃ for 2 hours each time, filtering, combining the aqueous extracts, and vacuumizing for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, and spray drying and pulverizing to obtain radix astragali water extract.
The invention has the beneficial effects that: on the basis of inhibiting prostatic hyperplasia and protecting liver, the ganoderma lucidum preparation is compatible with astragalus root, the effects of inhibiting prostatic hyperplasia, protecting and nourishing liver and improving immunity of various medicinal materials are synergistically exerted, and the obtained ganoderma lucidum tablets can inhibit prostatic hyperplasia, improve chronic hepatitis and effectively prevent relapse and deterioration of diseases.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise. Wherein:
FIG. 1 is a graph of the inhibitory effect of samples of various examples on LNCaP cell proliferation.
FIG. 2 is a graph showing the inhibitory effect of samples of various examples on the proliferation of 22RV1 cells.
FIG. 3 is a graph showing the repairing effect of samples of different examples on hydrogen peroxide damaged HepG2 cells.
FIG. 4 is a graph of the effect of samples from various examples on the release of NO by Raw264.7.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with examples are described in detail below.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described and will be readily apparent to those of ordinary skill in the art without departing from the spirit of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
Furthermore, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
Example 1:
the components of the ganoderma lucidum preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity comprise, by mass, 3.0% of ganoderma lucidum polysaccharide, 2.1% of astragalus polysaccharide, 0.001% of ganoderic acid A, 0.0005% of ganoderic acid G, 0.0005% of ganoderic acid D, 0.0008% of ganoderic ketone triol and 0.0005% of ganoderic acid DM.
The preparation method of the ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity comprises the following steps:
drying and crushing 1 part (by weight) of Hunong ganoderma lucidum No. 1 sporophore into 40 meshes, adding 8 times volume of 80% ethanol, soaking for 2h, extracting under hot reflux at 80 ℃ for 2 times, performing first extraction for 2h and second extraction for 1h, filtering, collecting filter residues, and performing vacuum filtration on the filtrate at 60 ℃ according to the weight ratio of 1: concentrating for 1 volume to obtain concentrated solution, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, spray drying, and pulverizing to obtain 0.05 weight parts of Ganoderma alcohol extract;
air-drying the filter residue, adding 10 times of water, extracting at 100 ℃ for 2 times, each time for 1h, finishing adding a small amount of water for washing, filtering, combining the water extracts, and vacuumizing at 60 ℃ for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, continuously concentrating the concentrated solution to 1/3 of the original volume, and spray drying and crushing to obtain 0.06 weight part of ganoderma aqueous extract;
pulverizing dried 4 parts of radix astragali to 2 mesh, adding 20 times volume of drinking water, extracting at 100 deg.C for 2 times, each for 2 hr, filtering, mixing water extracts, vacuum extracting at 70 deg.C for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, and spray drying and pulverizing to obtain 0.40 weight part of radix astragali extract;
mixing the obtained Ganoderma alcohol extract, Ganoderma water extract and radix astragali extract.
The experimental results are as follows:
inhibition assay of LNCaP, 22RV1 cells:
the cell concentration was 5X 104Tumor cells LNCaP, 22RV1 (purchased from cell resource center, Shanghai, science institute of sciences, China) suspension 180. mu.L/mL was added to a 96-well plate, after 24 hours 20. mu.L of the extract of example 1 was added, DMSO as a negative control and finasteride as a positive control, 3 replicates for each sample, after incubation at 37 ℃ for 72 hours at 5% concentration CO2, the old medium was aspirated off and 180. mu.L of colorless medium 1640 (ThermoFsher scientific, USA), 20. mu.L of AlamarBlue reagent 0.075mg/mL (ThermoFisher scientific, USA) was added, after discoloration, absorbance values were measured at 570 and 600nm using an enzyme-linked immunosorbent assay, and the effect of the samples on cell proliferation was calculated using the formula.
When the acting concentration of the sample in the example 1 is 100 mu g/mL, the inhibition rate of the prostate tumor cells LNCaP is 68.91%, and the inhibition rate of the prostate tumor cells LNCaP 22RV1 is 62.69%.
Detection of the repair rate of hydrogen peroxide to HepG2 cells:
HepG2 cells in the logarithmic growth phase were digested with pancreatin to a cell concentration of 1X 104mu.L of cell HepG2 (purchased from cell resource center of Shanghai Life sciences of China academy of sciences) suspension 180. mu.L was added to a 96-well plate, after 24 hours, 60. mu. mol/L of hydrogen peroxide treatment solution was added to the plate, and after 12 hours, the medium was aspirated and 20. mu.L of example 1 (working example 1) was added100 ug/mL) of the extract, DMSO as a negative control, Vitamin C (VC) as a positive control, 3 replicates per sample, 5% CO at 37 deg.C2After 72 hours of incubation under the conditions, the old medium was aspirated off and 180. mu.L of colorless 1640 medium (ThermoFsher scientific, USA) and 20. mu.L of 0.075mg/mL alamarBlue was added@The reagent (ThermoFisher scientific, USA) after color change, using enzyme-linked immunosorbent assay instrument to measure absorbance at 570 and 600nm, and using formula to calculate the effect of sample on cell proliferation.
When the sample of example 1 acted at a concentration of 100. mu.g/mL, the repair rate of hydrogen peroxide to repair damage to HepG2 was 52.56%.
Detection of the effect of Raw264.7 on NO release:
selecting good-growth log-phase RAW264.7 cells to prepare cell suspension, and adjusting cell density to 5 × 105mL, at 180 μ L cell suspension per well, in 96-well plates. And (4) measuring the light absorption values of sodium nitrite solutions with different concentrations at 543nm by using Griess reaction, and drawing an NO standard curve. The amount of NO released from macrophages stimulated by the extract samples of example 1 (working concentration 100. mu.g/mL) was determined, and PBS solution containing 1. mu.g/mLLPS were used as negative and positive controls, respectively, and the absorbance of the sample solution was measured at 543nm, and the amount of NO produced in the culture was calculated from the standard curve.
When the action concentration of the sample in example 1 was 100. mu.g/mL, the NO release amount was 42.19. mu.M/L.
Example 2:
the components of the ganoderma lucidum preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity comprise, by mass, 2.9% of ganoderma lucidum polysaccharide, 2.0% of astragalus polysaccharide, 0.001% of ganoderic acid A, 0.0004% of ganoderic acid G, 0.0005% of ganoderic acid D, 0.0006% of ganoderic ketone triol and 0.0005% of ganoderic acid DM.
The preparation method of the ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity comprises the following steps:
drying and crushing 1 part (by weight) of Hunong ganoderma lucidum No. 1 sporophore to 40 meshes, adding 8 times volume of 95% ethanol, soaking for 2h, extracting under reflux at 80 ℃ for 2 times, the first time for 2h, the second time for 1h, filtering and collecting filter residues, and performing vacuum filtration on the filtrate at 60 ℃ according to the weight ratio of 1: concentrating for 1 volume to obtain concentrated solution, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, spray drying, and pulverizing to obtain 0.04 weight parts of Ganoderma alcohol extract;
air-drying the filter residue, adding 10 times of water, extracting at 100 ℃ for 2 times, each time for 1h, finishing adding a small amount of water for washing, filtering, combining the water extracts, and vacuumizing at 60 ℃ for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, continuously concentrating the concentrated solution to 1/3 of the original volume, and spray drying and crushing to obtain 0.03 weight part of ganoderma aqueous extract;
pulverizing dried 4 parts of radix astragali to 2 mesh, adding 20 times volume of drinking water, extracting at 100 deg.C for 2 times, each for 2 hr, filtering, mixing water extracts, vacuum extracting at 70 deg.C for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, and spray drying and pulverizing to obtain 0.40 weight part of radix astragali extract;
mixing the obtained Ganoderma alcohol extract, Ganoderma water extract and radix astragali extract.
The experimental results are as follows:
inhibition assay of LNCaP, 22RV1 cells:
adding 180 μ L of suspension of tumor cells LNCaP, 22RV1 (purchased from cell resource center of Shanghai Life sciences of China academy of sciences) with cell concentration of 5 × 104/mL into 96-well plate, adding 20 μ L of the extract sample of example 1 after 24h, taking DMSO as negative control and finasteride as positive control, 3-fold each sample, culturing at 37 deg.C and CO2 concentration of 5% for 72h, aspirating the old culture medium, adding 180 μ L of colorless culture medium (ThermoF1640 sher scientific Co., USA), and adding 20 μ L of alamarBlue with cell concentration of 20.075mg/mL@The reagent (ThermoFisher scientific, USA) after color change, using enzyme-linked immunosorbent assay instrument to measure absorbance at 570 and 600nm, and using formula to calculate the effect of sample on cell proliferation.
When the acting concentration of the sample in example 2 is 100 mu g/mL, the inhibition rate of the prostate tumor cells LNCaP is 39.81 percent, and the inhibition rate of the prostate tumor cells 22RV1 is 38.59 percent.
Detection of the repair rate of hydrogen peroxide to HepG2 cells:
HepG2 cells in the logarithmic growth phase were digested with pancreatin to a cell concentration of 1X 104mu.L of cell HepG2 (purchased from cell resource center of Shanghai Life sciences of China academy of sciences) suspension 180. mu.L was added to a 96-well plate, after 24 hours, 60. mu. mol/L of hydrogen peroxide treatment solution was added to the plate, after 12 hours, the medium was aspirated, 20. mu.L of the sample of the extract of example 1 (working concentration 100. mu.g/mL) was added, DMSO as a negative control and Vitamin C (VC) as a positive control, each sample was repeated 3 times, and CO was added at 37 ℃ at a concentration of 5%2After 72 hours of incubation under these conditions, the old medium was aspirated off and 180. mu.L of colorless 1640 medium (ThermoFsher scientific, USA) was added, 20. mu.L, 0.075mg/mL of alamarBlue@The reagent (ThermoFisher scientific, USA) after color change, using enzyme-linked immunosorbent assay instrument to measure absorbance at 570 and 600nm, and using formula to calculate the effect of sample on cell proliferation.
When the sample of example 2 acted at a concentration of 100. mu.g/mL, the repair rate of hydrogen peroxide to repair damage to HepG2 was 39.14%.
Detection of the effect of Raw264.7 on NO release:
selecting good-growth log-phase RAW264.7 cells to prepare cell suspension, and adjusting cell density to 5 × 105mL, at 180 μ L cell suspension per well, in 96-well plates. And (4) measuring the light absorption values of sodium nitrite solutions with different concentrations at 543nm by using Griess reaction, and drawing an NO standard curve. The amount of NO released from macrophages stimulated by the extract samples of example 2 (working concentration 100. mu.g/mL) was determined, and PBS solution containing 1. mu.g/mLLPS were used as negative and positive controls, respectively, and the absorbance of the sample solution was measured at 543nm, and the amount of NO produced in the culture was calculated from the standard curve.
When the acting concentration of the sample in example 2 was 100. mu.g/mL, the NO release amount was 28.53. mu.M/L.
Example 3 (comparative example):
the ganoderma lucidum preparation with the triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity comprises, by mass, 2.18% of ganoderma lucidum polysaccharide and 1.90% of astragalus polysaccharide.
The preparation method of the ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity comprises the following steps:
drying and pulverizing 1 part (by weight) of Hunong Ganoderma lucidum No. 1 fruiting body to 40 mesh, adding 10 times volume of water, extracting at 100 deg.C for 2 times (each for 1 hr), washing with small amount of water, filtering, mixing water extracts, vacuum at 60 deg.C for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, continuously concentrating the concentrated solution to 1/3 of the original volume, and spray drying and crushing to obtain 0.03 weight part of ganoderma aqueous extract;
pulverizing dried 4 parts of radix astragali to 2 mesh, adding 20 times volume of drinking water, extracting at 100 deg.C for 2 times, each for 2 hr, filtering, mixing water extracts, vacuum extracting at 70 deg.C for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, and spray drying and pulverizing to obtain 0.40 weight part of radix astragali extract;
mixing the obtained Ganoderma aqueous extract and radix astragali extract.
When the acting concentration of the sample in example 3 is 100 mu g/mL, the inhibition rate of the prostate tumor cells LNCaP is 11.25 percent, and the inhibition rate of the prostate tumor cells 22RV1 is 9.18 percent.
When the sample of example 3 was acted on at a concentration of 100. mu.g/mL, it was treated with H2O2The repair rate for damage repair of HepG2 was 2.56%.
When the acting concentration of the sample in example 3 was 100. mu.g/mL, the NO release amount was 15.46. mu.M/L.
Example 4 (comparative example):
the components of the ganoderma lucidum preparation with triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity comprise, by mass, 3.68% of ganoderma lucidum polysaccharide, 0.0017% of ganoderic acid A, 0.0006% of ganoderic acid G, 0.0008% of ganoderic acid D, 0.0009% of ganoderic ketone triol and 0.0005% of ganoderic acid DM.
The preparation method of the ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity comprises the following steps:
drying and crushing 2 parts (by weight) of Hunong ganoderma lucidum No. 1 sporocarp to 2 meshes, adding 8 times of 80% ethanol by volume, soaking for 2 hours, performing hot reflux extraction at 80 ℃ for 2 times, performing first time for 2 hours and performing second time for 1 hour, filtering and collecting filter residues, and performing vacuum filtration on the filtrate at 60 ℃ according to the weight ratio of 1: concentrating for 1 volume to obtain concentrated solution, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, spray drying, and pulverizing to obtain 0.10 weight parts of Ganoderma alcohol extract;
air-drying the filter residue, adding 10 times of water, extracting at 100 ℃ for 2 times, each time for 1h, finishing adding a small amount of water for washing, filtering, combining the water extracts, and vacuumizing at 60 ℃ for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, spray drying, and pulverizing to obtain 0.12 weight parts of Ganoderma aqueous extract;
mixing the obtained Ganoderma alcohol extract and Ganoderma water extract.
When the acting concentration of the sample in example 4 is 100 mu g/mL, the inhibition rate of the prostate tumor cell LNCaP is 19.51 percent, and the inhibition rate of the prostate tumor cell 22RV1 is 22.73 percent.
When the sample of example 4 was acted on at a concentration of 100. mu.g/mL, it was treated with H2O2The repair rate for damage repair of HepG2 was 13.99%.
When the acting concentration of the sample in example 4 was 100. mu.g/mL, the NO release amount was 14.44. mu.M/L.
Example 5:
the preparation with the triple effects of inhibiting the hyperplasia of prostate, protecting liver and improving immunity comprises, by mass, 3.0% of ganoderan, 2.1% of astragalus polysaccharide, 0.001% of ganoderic acid A, 0.0005% of ganoderic acid G, 0.0005% of ganoderic acid D, 0.0008% of ganoderic ketone triol, 0.0005% of ganoderic acid DM and the balance of water.
The components of the preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity are purchased from commercial markers.
When the acting concentration of the sample in example 5 is 100 mug/mL, the inhibition rate of the prostate tumor cell LNCaP is 63.37%, and the inhibition rate of the prostate tumor cell 22RV1 is 57.83%.
When the sample of example 5 was acted on at a concentration of 100. mu.g/mL, it was treated with H2O2The repair rate for repair of HepG2 injury was 47.10%.
When the acting concentration of the sample in example 5 was 100. mu.g/mL, the NO release amount was 36.94. mu.M/L.
Example 6 (comparative example):
the preparation with the triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity comprises, by mass, 3.0% of ganoderma lucidum polysaccharide, 2.1% of astragalus polysaccharide and the balance of water.
The components of the preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity are purchased from commercial markers.
When the acting concentration of the sample in example 6 is 100 mug/mL, the inhibition rate of the prostate tumor cells LNCaP is 8.12 percent, and the inhibition rate of the prostate tumor cells 22RV1 is 6.52 percent.
When the sample of example 6 was acted on at a concentration of 100. mu.g/mL, it was treated with H2O2The repair rate for repairing HepG2 injury was 6.01%.
When the acting concentration of the sample in example 6 was 100. mu.g/mL, the NO release amount was 26.13. mu.M/L.
Example 7 (comparative example):
the preparation with the triple effects of inhibiting the prostatic hyperplasia, protecting the liver and improving the immunity comprises, by mass, 0.001% of ganoderic acid A, 0.0005% of ganoderic acid G, 0.0005% of ganoderic acid D, 0.0008% of ganoderic ketone triol, 0.0005% of ganoderic acid DM and the balance of water.
The components of the preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity are purchased from commercial markers.
When the acting concentration of the sample in example 7 is 100 mu g/mL, the inhibition rate of the prostate tumor cell LNCaP is 14.73 percent, and the inhibition rate of the prostate tumor cell 22RV1 is 13.53 percent.
When the sample of example 7 was acted on at a concentration of 100. mu.g/mL, it was treated with H2O2The repair rate for damage repair of HepG2 was 30.29%.
When the acting concentration of the sample of example 7 was 100. mu.g/mL, the NO release amount was 15.42. mu.M/L.
Example 8 (comparative example):
the preparation with the triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity comprises, by mass, 2.18% of ganoderan, 0.012% of ganoderic acid A, 0.006% of ganoderic acid F, 0.006% of ganoderic triol, 0.006% of ganoderic alcohol B and the balance of water.
The components of the preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity are purchased from commercial markers.
The inhibition rate of LNCaP, 22RV1 cells was determined as in example 1: when the acting concentration of the sample is 100 mu g/mL, the inhibition rate of the prostate tumor cells LNCaP is 12.76 percent, and the inhibition rate of 22RV1 is 16.20 percent.
The repair rate of hydrogen peroxide on HepG2 cells was tested as in example 1: when the acting concentration of the sample is 100 mu g/mL, the repair rate of the hydrogen peroxide on the damage repair of HepG2 is 10.52 percent.
In conclusion, on the basis of inhibiting prostatic hyperplasia and protecting liver, the ganoderma lucidum preparation is compatible with astragalus to exert the efficacies of inhibiting prostatic hyperplasia, protecting and nourishing liver and improving immunity of various medicinal materials synergistically, and the obtained ganoderma lucidum tablet can inhibit prostatic hyperplasia, improve chronic hepatitis and effectively prevent relapse and deterioration of diseases.
It should be noted that the above-mentioned embodiments are only for illustrating the technical solutions of the present invention and not for limiting, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, which should be covered by the claims of the present invention.
Claims (2)
1. A ganoderma lucidum preparation with triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity is characterized in that:
the ganoderma preparation consists of a ganoderma alcohol extract, a ganoderma aqueous extract and an astragalus aqueous extract;
the preparation method of the ganoderma lucidum preparation comprises the following steps:
drying and crushing 1 part by weight of Hunong ganoderma lucidum No. 1 sporocarp to 40 meshes, adding 8 times of 80% ethanol by volume, soaking for 2 hours, performing hot reflux extraction at 80 ℃ for 2 times, performing first time for 2 hours, performing second time for 1 hour, filtering and collecting filter residues, and performing vacuum filtration on the filtrate at 60 ℃ according to the weight ratio of 1: concentrating for 1 volume to obtain concentrated solution, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, spray drying, and pulverizing to obtain 0.05 weight parts of Ganoderma alcohol extract;
air-drying the filter residue, adding 10 times of water, extracting at 100 ℃ for 2 times, each time for 1h, finishing adding a small amount of water for washing, filtering, combining the water extracts, and vacuumizing at 60 ℃ for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, continuously concentrating the concentrated solution to 1/3 of the original volume, and spray drying and crushing to obtain 0.06 weight part of ganoderma aqueous extract;
pulverizing dried 4 parts of radix astragali to 2 mesh, adding 20 times volume of drinking water, extracting at 100 deg.C for 2 times, each for 2 hr, filtering, mixing water extracts, vacuum extracting at 70 deg.C for 1: concentrating by volume of 1, centrifuging at high speed to remove impurities, concentrating the concentrated solution to 1/3 of the original volume, and spray drying and pulverizing to obtain 0.40 weight part of radix astragali extract;
mixing the obtained ganoderma alcohol extract, ganoderma aqueous extract and astragalus extract;
the Ganoderma preparation comprises ganoderan, Astragalus polysaccharides, ganoderic acid A, ganoderic acid G, ganoderic acid D, ganoderic ketotriol and ganoderic acid DM; wherein, the content of ganoderan is 2.5-3.5%, the content of astragalus polysaccharide is 1.8-2.4%, the content of ganoderic acid A is 0.0008-0.0012%, the content of ganoderic acid G is 0.0004-0.0006%, the content of ganoderic acid D is 0.0004-0.0006%, the content of ganoderic ketone triol is 0.0007-0.0009%, and the content of ganoderic acid DM is 0.0004-0.0006%.
2. The ganoderma lucidum preparation with the triple effects of inhibiting prostatic hyperplasia, protecting liver and improving immunity as claimed in claim 1, wherein: by mass percentage, the content of ganoderan is 3.0%, the content of astragalus polysaccharide is 2.1%, the content of ganoderic acid A is 0.001%, the content of ganoderic acid G is 0.0005%, the content of ganoderic acid D is 0.0005%, the content of ganoderic ketone triol is 0.0008%, and the content of ganoderic acid DM is 0.0005%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910234660.9A CN109793811B (en) | 2019-03-26 | 2019-03-26 | Ganoderma preparation with effects of inhibiting prostatic hyperplasia, protecting liver and enhancing immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910234660.9A CN109793811B (en) | 2019-03-26 | 2019-03-26 | Ganoderma preparation with effects of inhibiting prostatic hyperplasia, protecting liver and enhancing immunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109793811A CN109793811A (en) | 2019-05-24 |
| CN109793811B true CN109793811B (en) | 2021-06-25 |
Family
ID=66564033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910234660.9A Active CN109793811B (en) | 2019-03-26 | 2019-03-26 | Ganoderma preparation with effects of inhibiting prostatic hyperplasia, protecting liver and enhancing immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109793811B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780136A (en) * | 2010-03-17 | 2010-07-21 | 上海大学 | Medicine and food dual-purpose traditional Chinese medicine composition with anti-tumor activity and immunoregulation effect and application thereof |
| CN104840482A (en) * | 2015-05-05 | 2015-08-19 | 上海中医药大学附属龙华医院 | Chinese medicine effective component composition and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1120723C (en) * | 2000-04-12 | 2003-09-10 | 上海永业农科保健品有限公司 | Health-care lucid qanoderma product and its preparing process |
| CN105412210A (en) * | 2015-12-11 | 2016-03-23 | 杨石 | Health-care food composition |
| CN107050068A (en) * | 2017-05-15 | 2017-08-18 | 大德仟年生物技术有限公司 | The extracting method of Ganodenna Lucidum P.E and its application |
-
2019
- 2019-03-26 CN CN201910234660.9A patent/CN109793811B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780136A (en) * | 2010-03-17 | 2010-07-21 | 上海大学 | Medicine and food dual-purpose traditional Chinese medicine composition with anti-tumor activity and immunoregulation effect and application thereof |
| CN104840482A (en) * | 2015-05-05 | 2015-08-19 | 上海中医药大学附属龙华医院 | Chinese medicine effective component composition and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 101澄清剂用于灵芝黄芪精口服液的工艺研究;高志刚，等;《中国现代应用药学》;19971031;第14卷(第05期);全文 * |
| 灵芝对前列腺癌的作用机理;汪雯翰，等;《食用菌学报》;20181231;第25卷(第01期);第107-108页"1 诱导前列腺癌细胞凋亡"项下第一段 * |
| 金麒麟口服液的制剂和质量控制;章全才;《辽宁中医杂志》;19980131;第25卷(第01期);全文 * |
| 高效液相色谱法测定不同产地及品种灵芝三萜类成分的含量;贾红岩，等;《微生物学通报》;20170131;第44卷(第01期);摘要，正文第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109793811A (en) | 2019-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Antioxidant activity of Inonotus obliquus polysaccharide and its amelioration for chronic pancreatitis in mice | |
| WO2022116807A1 (en) | Method for preparing ganoderma lucidum extract oil rich in ganoderma lucidum triterpene | |
| KR101773081B1 (en) | Dolwoe fermented extracts comprising saponins as an active functional food ingredient and preparation method thereof | |
| He et al. | Research progress on extraction, purification, structure and biological activity of Dendrobium officinale polysaccharides | |
| CN104856968B (en) | A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof | |
| CN105168624B (en) | A kind of sulfathiazole and preparation method thereof | |
| CN112704712B (en) | Traditional Chinese medicine composition for eye care and preparation method and application thereof | |
| WO2020093510A1 (en) | Separation and purification method for polysaccharide in ganoderma lucidum spores | |
| Bi et al. | Biological and physicochemical properties of two polysaccharides from the mycelia of Grifola umbellate | |
| CN101062074A (en) | Compound of sphaeria sinensis and panax notoginseng extract and the application thereof in the preventing and treating of pulmonary fibrosis | |
| CN101856374A (en) | Anti-aging compound | |
| CN107496490B (en) | A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof | |
| CN109793811B (en) | Ganoderma preparation with effects of inhibiting prostatic hyperplasia, protecting liver and enhancing immunity | |
| KR101416671B1 (en) | Ginseng prosapogenin high concentration containing ginseng leaf or stem preparation using sonication and process for thereof | |
| CN106883306A (en) | A kind of extraction separation method of the sunflower stem core polysaccharide with antitumor activity | |
| CN114796305B (en) | Preparation method and application of licorice extract | |
| US11938161B2 (en) | Use of ginseng alcohol extract in sleep-promoting health care products or foods | |
| KR0168485B1 (en) | The production of ginseng steamed red essence | |
| Ma et al. | Inhibitory effect of fermented flammulina velutipes polysaccharides on mice intestinal inflammation | |
| CN106317155B (en) | A kind of reproducibility cucurbit alkane type triterpenoid and its preparation method and purposes | |
| CN107320697A (en) | A kind of pyemia for the treatment of causes composition of ARDS and its production and use | |
| CN113880962A (en) | Fig polysaccharide and extraction method and application thereof | |
| KR101381507B1 (en) | A Red ginseng using microwave and process for thereof | |
| CN1615959A (en) | Chines medicine capsule preparation for treating skin diseases | |
| CN107397776A (en) | A kind of Chinese medicine composition for treating disease in the liver and gallbladder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |